Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Merck Stock: Attractive Dividend Play at Current Levels

Stock MarketsOct 13, 2021 12:31PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. Merck Stock: Attractive Dividend Play at Current Levels

Merck (MRK) is one of the largest international healthcare companies, focusing on delivering innovative health solutions through its prescription medicines, vaccines, biologic therapies, animal health products, and other related pharmaceuticals.

Since completing its spinoff with women's health company Organon in June, the company's operations are mainly split into two segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable. (See Insiders’ Hot Stocks on TipRanks)

Merck's diversified portfolio of pharmaceuticals and animal health medicines comprises a great stream of cash flows for the company. Merck is highly profitable, offering a strong dividend, while the stock is trading at an attractive valuation multiple. For this reason, I am bullish on the stock.

Results Remain Strong

Merck's portfolio of pharmaceutical brands provides the company some of the most stable and reliable cash flows in the industry.

Merck's latest quarterly results once again reflected its portfolio's strength. In Q2, revenues grew 22% to $11.4 billion, beating analysts’ estimates by $200 million. Adjusted net income came in at $3.3 billion, or $1.31 per share, versus $2.5 billion, or $1.02 per share, in the prior-year period.

While COVID-19 adversely affected the company last year, the pandemic appears to have had positive impacts on Merck's recent results. The company estimates that the net favorable benefit of the pandemic's recovery to year-over-year sales growth was approximately $900 million in Q2.

Specifically, pharmaceutical revenues expanded 18% to $10 billion, and note that this is with a 4% currency exchange drag on results. Notable advances include Keytruda (treats cancers such as melanoma and non-small cell lung cancer), which reported sales growth of 20% to $4.1 billion.

Due to Keytruda continuing to see more eminent uptick rates across a number of indications, it is likely that its sales are to keep growing at a strong pace moving forward.

Further, Merck’s HPV vaccine Gardasil's revenues surged 78% to $1.2 billion, powered by the ongoing recovery in the U.S. and China.

Reasonably Priced

Following Q2's strong results, Merck provided updated guidance for the full year. Subsequent to the Organon spinoff, Merck estimates revenues of $46.4 billion to $47.4 billion for the year (previously $45.8 billion to $47.8 billion), which indicates a 12% to 14% growth year-over-year. Furthermore, adjusted EPS is forecasted to be in a range of $5.47 to $5.57.

At the midpoint of this EPS estimate ($5.52), the stock is currently trading with a (sort of forward) P/E of 14.4 attached, which is a rather inexpensive multiple in the current environment.

Further, the stock offers a yield of around 3.2%, which is one of the highest in big pharma, and a great yield in the market generally these days.

Merck's latest DPS hike was by a solid 6.6%, and it's quite likely that future hikes (with the next one likely scheduled this November) are to come.

Wall Street’s Take

Turning to Wall Street, Merck has a Moderate Buy consensus rating, based on six Buys, four Holds, and zero Sells assigned in the past three months. At $93.30, the average Merck price target implies 17.2% upside potential.

Disclosure: At the time of publication, Nikolaos Sismanis did not have a position in any of the securities mentioned in this article.

Disclaimer: The information contained in this article represents the views and opinion of the writer only, and not the views or opinion of TipRanks or its affiliates, and should be considered for informational purposes only. TipRanks makes no warranties about the completeness, accuracy or reliability of such information. Nothing in this article should be taken as a recommendation or solicitation to purchase or sell securities. Nothing in the article constitutes legal, professional, investment and/or financial advice and/or takes into account the specific needs and/or requirements of an individual, nor does any information in the article constitute a comprehensive or complete statement of the matters or subject discussed therein. TipRanks and its affiliates disclaim all liability or responsibility with respect to the content of the article, and any action taken upon the information in the article is at your own and sole risk. The link to this article does not constitute an endorsement or recommendation by TipRanks or its affiliates. Past performance is not indicative of future results, prices or performance.

Merck Stock: Attractive Dividend Play at Current Levels
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email